RJA
EW icon

Ross\Johnson & Associates’s Edwards Lifesciences EW Stock Holding History

Ross\Johnson & Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271 Buy
3
+1
+50% +$84 ﹤0.01% 195
2026
Q1 		$160 Sell
2
-9
-82% -$742 ﹤0.01% 188
2025
Q4 		$938 Buy
11
+9
+450% +$739 0.02% 100
2025
Q3 		$156 Hold
2
– – ﹤0.01% 185
2025
Q2 		$156 Hold
2
– – ﹤0.01% 185
2025
Q1 		$144 Buy
+2
New +$143 ﹤0.01% 334

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Ross\Johnson & Associates's EW Position: Q2 2026 in Review

Ross\Johnson & Associates increased its Edwards Lifesciences (EW) stake by 50% in Q2 2026, buying an estimated $84 and bringing the position to 3 shares worth $271. The position accounts for ﹤0.01% of the portfolio, ranked #195.

Ross\Johnson & Associates first reported a position in EW in Q1 2025 and has held it in 6 quarters since. The position peaked at $938 in Q4 2025. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Ross\Johnson & Associates held 3 shares of Edwards Lifesciences worth $271 as of Q2 2026.
  • Ross\Johnson & Associates bought 1 Edwards Lifesciences share in Q2 2026, an estimated $84.
  • Edwards Lifesciences made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #195 holding.
  • Ross\Johnson & Associates first reported a position in Edwards Lifesciences in Q1 2025 and has held it in 6 quarters since.
  • Ross\Johnson & Associates's Edwards Lifesciences position peaked at $938 in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.